Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aquestive Therapeutics In...

    NASDAQ: AQST · Real-Time Price · USD
    3.29
    0.04 (1.23%)
    At close: Jun 23, 2025, 3:48 PM
    1.23%
    Bid 3.28
    Market Cap 326.79M
    Revenue (ttm) 54.23M
    Net Income (ttm) -54.24M
    EPS (ttm) -0.58
    PE Ratio (ttm) -5.67
    Forward PE -5.76
    Analyst Buy
    Ask 3.32
    Volume 902,435
    Avg. Volume (20D) 1,521,091
    Open 3.20
    Previous Close 3.25
    Day's Range 3.17 - 3.40
    52-Week Range 2.12 - 5.80
    Beta 1.93

    About AQST

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AQST
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Aquestive Therapeutics Inc. is scheduled to release its earnings on Aug 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -19.65%
    Aquestive Therapeutics shares are trading lower af... Unlock content with Pro Subscription
    3 months ago
    +2.2%
    Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results
    news image

    2 weeks ago · seekingalpha.com

    Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share

    Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and...

    news image

    1 month ago · seekingalpha.com

    Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript

    Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...

    news image

    1 month ago · zacks.com

    Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say

    While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key me...

    news image

    1 month ago · zacks.com

    Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

    Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.

    news image

    1 month ago · seekingalpha.com

    Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential

    AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, w...

    news image

    3 months ago · seekingalpha.com

    Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy

    Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mire...

    Add to Watchlist